Home > Resources > Whitepapers > PHARMACOVIGILANCE AND RISK MANAGEMENT CONSIDERATION FOR RARE DISEASE GENE THERAPIES

PHARMACOVIGILANCE AND RISK MANAGEMENT CONSIDERATION FOR RARE DISEASE GENE THERAPIES

July 17, 2019

The development of a pharmacovigilance and risk management system to support a gene therapy for a rare genetic disease requires consideration of the specific challenges and nuances that novel therapies present throughout the lifetime of the product.

Spotlight

BDI Pharma, Inc

BDI Pharma is the nation’s fastest growing, privately-held distributor of specialty pharmaceutical products. With more than two decades of expertise in the industry, the company consistently redefines niche distribution providing commercialization solutions beyond those of the traditional wholesaler. Through an offering that includes innovative supply chain solutions, reimbursement assistance, specialized product knowledge, 24/7 emergency availability and urgent-need delivery capabilities, BDI Pharma serves as a true ally to both pharmaceutical manufacturers and healthcare providers.

OTHER WHITEPAPERS

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

PHARMACOVIGILANCE AND RISK MANAGEMENT CONSIDERATION FOR RARE DISEASE GENE THERAPIES